BeOne Medicines raises 2026 outlook as Q2 revenue surges 30%

BeOne Medicines Ltd, a global oncology biotech, reported total revenue of $1.7 billion for the second quarter of 2026, up 30 percent year-on-year, as robust global sales of its flagship blood cancer drug Brukinsa prompted the company to raise its full-year outlook.

The company, which is listed in the United States, Hong Kong and Shanghai, said in a statement that total product revenue rose 29 percent to $1.7 billion.

Net income on a GAAP basis jumped 151 percent to $237 million, which the company attributed mainly to revenue growth and improved operating leverage. Operating income on the same basis surged 270 percent to $325 million.

Brukinsa generated $1.2 billion in global sales during the quarter, rising 31 percent year-on-year, including $893 million in the United States, also up 31 percent.

Sales of Tevimbra, an immunotherapy, rose 18 percent to $229 million, while revenue from licensed products from Amgen Inc increased 25 percent to $157 million.

Gross margin improved to 90 percent from 87 percent a year earlier, supported by a higher contribution from Brukinsa and lower production costs for Brukinsa and Tevimbra, the company said.

Following the strong performance, BeOne raised its 2026 total revenue guidance to between $6.6 billion and $6.8 billion, from a previous range of $6.3 billion to $6.5 billion. It also lifted its GAAP operating income forecast to a range of $1 billion to $1.1 billion, from $750 million to $850 million.

"These strong second-quarter results underscore our continued growth as a global oncology leader," John Oyler, co-founder, chairman and CEO of BeOne, said in the statement.

Oyler added that BeOne was well positioned for its next phase of global growth, supported by differentiated capabilities spanning drug discovery, clinical development, manufacturing and commercialization.